ISIN:CA09076M1014

BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program

VANCOUVER, BC, March 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into an agreement with Bioanalytical Systems, Inc. d...

2021-03-18 20:09 4527

BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs

VANCOUVER, British Columbia, March 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into a major bioproduction agreement w...

2021-03-15 20:00 3031

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer app...

2021-03-01 21:00 4798

BioVaxys Announces Appointment To Its Scientific Advisory Board

VANCOUVER, B.C., Feb. 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, today announced the appointment of Kartik Chandran Ph.D....

2021-02-22 21:00 2194

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC:L MNGF)("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Procare Health Iberia, S.L., ofBarcelona, Spain ("Procare Health"...

2021-02-10 21:26 4886

Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged

VANCOUVER, BC, Jan. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to announce that it has initiated the clinical development program for Covid-T™, the Company's novel diagnostic platform for detecting T-cell activity. T...

2021-01-28 21:46 5184

BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program

VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is ple...

2021-01-25 21:00 3087

BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens

VANCOUVER, British Columbia, Dec. 21, 2020 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys") announced today that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine tech...

2020-12-21 21:00 2410
12

Week's Top Stories